IGNYTE Trial Data Showed 24% Objective Response Rate for Tudriqev

Introduction

Clinical data from Replimune's IGNYTE trial played a central role in the U.S. approval of Tudriqev (vusolimogene oderparepvec-wtpg) for advanced melanoma. The study showed that 24.2% of efficacy-evaluable patients achieved an objective response when treated with Tudriqev in combination with nivolumab.

The results were particularly significant because the patients enrolled had advanced cutaneous melanoma that had progressed following prior anti-PD-1-based therapy, leaving them with limited treatment options. The FDA subsequently granted Tudriqev accelerated approval on August 6, 2026.

IGNYTE Evaluated a Difficult-to-Treat Patient Population

The IGNYTE study was an open-label, multiregional, single-arm trial involving 140 adults with Stage IIIB, IIIC, or IV unresectable advanced melanoma.

Patients had experienced disease progression after receiving at least eight consecutive weeks of prior anti-PD-1-based treatment. Of the 140 enrolled patients, 91 patients who had at least one non-injected lesion were included in the efficacy-evaluable population.

This population is important because melanoma that progresses after checkpoint inhibitor therapy can be particularly difficult to treat, creating a significant need for alternative therapeutic approaches.

24.2% Objective Response Rate

The key efficacy finding from IGNYTE was an objective response rate (ORR) of 24.2% among the 91 efficacy-evaluable patients.

In practical terms, approximately one in four evaluable patients experienced a measurable reduction in tumor burden according to the study's response criteria.

The reported 95% confidence interval for the ORR was 15.8% to 34.3%, providing additional context around the estimated response rate.

The result became one of the principal pieces of evidence supporting Tudriqev's accelerated approval.

Responses Also Lasted Over a Year

Response rate was not the only important finding from the study.

Among responding patients, the median duration of response was 14.1 months. This means that half of the observed responses lasted longer than 14.1 months and half lasted less, based on the study's statistical estimate.

The durability of responses was an important part of the FDA's assessment because a temporary tumor reduction may have less clinical significance than a response that can be maintained over a substantial period.

Evidence of Activity Beyond Injected Tumors

One notable feature of the IGNYTE evaluation was the inclusion of patients with non-injected lesions in the efficacy-evaluable population.

This matters because Tudriqev is administered directly into tumors. Demonstrating responses in tumors that were not directly injected provides evidence of potential systemic anti-tumor activity, rather than simply showing an effect at the injection site.

The trial therefore provided data supporting the concept that the treatment could stimulate an immune response capable of affecting cancer beyond the tumors directly exposed to the therapy.

Tudriqev's Mechanism of Action

Tudriqev is an oncolytic immunotherapy based on a genetically modified herpes simplex virus.

The therapy is injected directly into tumors and is designed to replicate within cancer cells, contributing to tumor destruction while stimulating an immune response against cancer.

It is administered in combination with nivolumab, a PD-1-blocking immunotherapy. The combination is intended to enhance the body's ability to recognize and attack cancer cells.

This approach differs from conventional systemic checkpoint inhibition because Tudriqev is designed to combine direct viral activity within tumors with broader immune-system activation.

Why the 24% Result Was Important

The response rate needs to be considered in the context of the patients who participated in the study.

These were not newly diagnosed melanoma patients receiving first-line treatment. They had already experienced disease progression after anti-PD-1-based therapy.

That makes the observed response rate particularly relevant to the treatment's approved population, where therapeutic alternatives are limited.

FDA materials and recent reporting have highlighted the unmet need in this setting, while the IGNYTE data provided evidence that Tudriqev could produce meaningful responses in some patients after previous immunotherapy had failed.

The Single-Arm Design Created Regulatory Questions

Despite the encouraging results, the IGNYTE data also had an important limitation.

The trial was single-arm, meaning patients did not receive Tudriqev in a randomized comparison against a separate control treatment.

This made it more difficult to determine precisely how much of the observed benefit was attributable to Tudriqev itself, particularly because patients received Tudriqev in combination with nivolumab.

The issue became a major part of Replimune's regulatory discussions with the FDA and contributed to the company's earlier difficulties securing approval.

Advisory Committee Supported the Clinical Meaning of the Results

The significance of the IGNYTE data was reinforced during an FDA advisory committee meeting in July 2026.

Committee members voted 10–3 that the efficacy results were evaluable and clinically meaningful. The vote represented an important regulatory turning point after the therapy had previously faced two FDA rejections.

Although advisory committee recommendations are not binding on the FDA, the favorable vote provided additional support for Replimune's application.

Data Supported Accelerated Approval

The FDA ultimately granted Tudriqev accelerated approval based on objective response rate and duration of response from the clinical evidence.

The approval covers Tudriqev in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease has progressed following an anti-PD-1 antibody-based regimen.

However, the approval does not eliminate the need for additional evidence. Under the accelerated approval pathway, Replimune must conduct confirmatory research to verify and further characterize Tudriqev's clinical benefit.

Phase 3 Trial Will Provide the Next Test

The encouraging IGNYTE results now need to be supported by evidence from a later-stage comparative study.

Replimune's ongoing Phase 3 IGNYTE-3 trial is evaluating Tudriqev plus nivolumab against physician's choice of treatment. The study is expected to provide more rigorous evidence of the treatment's clinical benefit, with key results anticipated around 2030.

This trial will be particularly important because the earlier IGNYTE study did not include a randomized control arm.

Implications for Replimune

For Replimune, the 24.2% response rate represents an important clinical and commercial milestone.

Tudriqev is the company's first approved product, and the IGNYTE results provided the evidence needed to move the therapy from clinical development into commercialization.

The company must now demonstrate that the treatment's clinical benefit can be confirmed in a controlled Phase 3 setting while establishing manufacturing, distribution, reimbursement, and treatment-center infrastructure.

Conclusion

The 24.2% objective response rate in the IGNYTE trial was a central piece of evidence behind Tudriqev's accelerated FDA approval.

The combination of a roughly one-in-four response rate and a 14.1-month median duration of response demonstrated meaningful anti-tumor activity in patients whose advanced melanoma had progressed after anti-PD-1-based therapy.

At the same time, the single-arm design means the results do not provide the same level of evidence as a randomized controlled trial. The ongoing Phase 3 IGNYTE-3 study will therefore be critical in determining whether the promising response signal observed in IGNYTE translates into confirmed clinical benefit.

For Tudriqev, the 24% response rate opened the door to FDA approval—but the next generation of clinical evidence will determine how firmly the therapy establishes itself in the melanoma treatment landscape.